383 related articles for article (PubMed ID: 19507806)
1. Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain.
Wallace M; Moulin DE; Rauck RL; Khanna S; Tudor IC; Skowronski R; Thipphawong J
J Opioid Manag; 2009; 5(2):97-105. PubMed ID: 19507806
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Hale M; Tudor IC; Khanna S; Thipphawong J
Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127).
Wallace M; Skowronski R; Khanna S; Tudor IC; Thipphawong J
Curr Med Res Opin; 2007 May; 23(5):981-9. PubMed ID: 17519065
[TBL] [Abstract][Full Text] [Related]
4. Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study.
Wallace M; Rauck RL; Moulin D; Thipphawong J; Khanna S; Tudor IC
Int J Clin Pract; 2007 Oct; 61(10):1671-6. PubMed ID: 17877652
[TBL] [Abstract][Full Text] [Related]
5. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.
Binsfeld H; Szczepanski L; Waechter S; Richarz U; Sabatowski R
Pain Pract; 2010; 10(5):404-15. PubMed ID: 20384968
[TBL] [Abstract][Full Text] [Related]
6. Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain.
Richarz U; Waechter S; Sabatowski R; Szczepanski L; Binsfeld H
Pain Pract; 2013 Jan; 13(1):30-40. PubMed ID: 22510252
[TBL] [Abstract][Full Text] [Related]
7. An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain.
Hanna M; Tuca A; Thipphawong J
BMC Palliat Care; 2009 Sep; 8():14. PubMed ID: 19754935
[TBL] [Abstract][Full Text] [Related]
8. Open-label study to evaluate the efficacy and safety of extended-release hydromorphone in patients with chronic neuropathic pain.
Nalamachu S; Ruck D; Nalamasu R; Fasbinder S; Bansal R
J Opioid Manag; 2013; 9(1):43-9. PubMed ID: 23709303
[TBL] [Abstract][Full Text] [Related]
9. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.
Palangio M; Northfelt DW; Portenoy RK; Brookoff D; Doyle RT; Dornseif BE; Damask MC
J Pain Symptom Manage; 2002 May; 23(5):355-68. PubMed ID: 12007754
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of OROS® hydromorphone ER in adults with chronic noncancer and cancer pain: pooled analysis of 13 studies.
Hale ME; Wallace MS; Taylor DR; Kutch M; Nalamachu S
J Opioid Manag; 2012; 8(5):299-314. PubMed ID: 23247907
[TBL] [Abstract][Full Text] [Related]
11. A prospective multicentre study to evaluate the efficacy and tolerability of osmotic release oral system (OROS) hydromorphone in opioid-naive cancer patients: Results of the Korean South West Oncology Group study.
Song EK; Shim H; Han HS; Sun D; Lee SI; Kang MH; Lee K; Cho D; Cho IS; Park SY; Kim S; Yim CY
Pain Res Manag; 2015; 20(6):293-9. PubMed ID: 26474382
[TBL] [Abstract][Full Text] [Related]
12. Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain.
Wallace M; Rauck RL; Moulin D; Thipphawong J; Khanna S; Tudor IC
J Int Med Res; 2008; 36(2):343-52. PubMed ID: 18380946
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the sustained-release hydromorphone in neuropathic pain management: pooled analysis of three open-label studies.
Moulin DE; Richarz U; Wallace M; Jacobs A; Thipphawong J
J Pain Palliat Care Pharmacother; 2010 Sep; 24(3):200-12. PubMed ID: 20718640
[TBL] [Abstract][Full Text] [Related]
14. OROS hydromorphone prolonged release: a review of its use in the management of chronic, moderate to severe pain.
Carter NJ; Keating GM
CNS Drugs; 2010 Apr; 24(4):337-61. PubMed ID: 20297858
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.
Hauber AB; Fleischmann J; Lothgren M; Wilson M; Lam A; Dubois D; Sabatowski R
J Opioid Manag; 2011; 7(4):287-96. PubMed ID: 21957828
[TBL] [Abstract][Full Text] [Related]
16. Safety and Tolerability of Once-Daily OROS(®) hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies.
Nalamachu SR; Kutch M; Hale ME
J Pain Symptom Manage; 2012 Dec; 44(6):852-65. PubMed ID: 22795050
[TBL] [Abstract][Full Text] [Related]
17. OROS® hydromorphone in chronic pain management: when drug delivery technology matches clinical needs.
Coluzzi F; Mattia C
Minerva Anestesiol; 2010 Dec; 76(12):1072-84. PubMed ID: 21102402
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness and safety of OROS® hydromorphone in break-through cancer pain treatment: a multicenter, prospective, open-label study in Korean patients.
Lee KH; Kim MK; Hyun MS; Kim JY; Park KU; Song HS; Lee SA; Lee WS; Bae SH; Ryoo HM; Cho YY
J Opioid Manag; 2012; 8(4):243-52. PubMed ID: 22941852
[TBL] [Abstract][Full Text] [Related]
19. Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis.
Rauck R; Rapoport R; Thipphawong J
Pain Pract; 2013 Jan; 13(1):18-29. PubMed ID: 22537100
[TBL] [Abstract][Full Text] [Related]
20. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
